dendritic cell-cytokine-induced killer cells + Kanglaite + bevacizumab

This combination therapy integrates three distinct therapeutic modalities: the anti-angiogenic monoclonal antibody bevacizumab, the botanical-derived antineoplastic microemulsion Kanglaite, and autologous dendritic cell-cytokine-induced killer (DC-CIK) cell therapy. Bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and normalize tumor vasculature. Kanglaite, an injectable microemulsion extracted from the seeds of *Coix lacryma-jobi*, promotes tumor cell apoptosis and induces cell cycle arrest, particularly in the G2/M phase, while also inhibiting the PI3K/Akt/mTOR pathway. DC-CIK therapy provides a dual-pronged immune attack, utilizing dendritic cells to present tumor antigens and CIK cells (CD3+CD56+ effector cells) to exert non-MHC-restricted cytotoxicity against tumor cells. This triple combination is primarily investigated in China for the treatment of advanced malignancies, such as non-small cell lung cancer (NSCLC) and hepatocellular carcinoma, aiming to synergistically enhance anti-tumor efficacy, overcome drug resistance, and improve the patient's immune status compared to standard chemotherapy or monotherapy.

Other names

DC-CIK + Kanglaite + bevacizumabDC-CIK + KLT + bevacizumabbevacizumab + Kanglaite + DC-CIKbevacizumab combined with Kanglaite and DC-CIK